NMR measurements of NMR biomarker GlycA
US10852293B2 · kind B2 · utility
2Cited by
10References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2016 |
| Grant date | Dec 1, 2020 |
| Priority date | — |
| Expiry date | Sep 14, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/50
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.